Jul. 2 at 6:34 PM
$CPIX
Interesting fact:
They may have 41 patients on their OLE Trial. That would be one heck of a dataset for OLE, If that data is good, it would be very convincing to FDA that this drug works. IMHO.
Here is the reasoning: At the end of Phase 2, there were 41 patients completed the trial in total. Assuming none of the patients quit OLE, then there would be 41 in OLE at the end (Mid 2025).
Here is a snaphot of the Trial 2 years ago, and there were already 24 patients on OLE. All patients decided to join OLE.
Maybe they know it works because this is an open label, the data is known during the trial.
